Articles dans des revues avec comité de lecture (86)
  1. 1. Bouchart, C., Azurmendi Senar, O., Navez, J., Verset, L., Boisson, A., Hein, M., Stosic, K., Quertinmont, E., Tafciu, V., Zhao, S., Mas, L., D'Haene, N., Van Gestel, D., Moretti, L., Michiels, E., Rooman, I., Detours, V., Bachet, J.-B., Demetter, P., Willard-Gallo, K., Nicolle, R., Arsenijevic, T., & Van Laethem, J.-L. (2026). Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. British Journal of Cancer. doi:10.1038/s41416-025-03274-0
  2. 2. Racu, M.-L., Schiavo, A. A., Van Campenhout, C., De Nève, N., Masuy, T., Maris, C., Decaestecker, C., Remmelink, M., Salmon, I., & D'Haene, N. (2024). Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas. Experimental and molecular pathology, 139, 104920. doi:10.1016/j.yexmp.2024.104920
  3. 3. Francisse, S., Gkolfakis, P., Fernandez Y Viesca, M., Mans, L., Demols, A., Pezzullo, M., Loi, P., Navez, J., Closset, J., Bali, M. A., Van Wettere, M., D'Haene, N., Demetter, P., Verset, L., Bouchart, C., Lemmers, A., Devière, J., Delhaye, M., Van Laethem, J.-L., & Arvanitakis, M. (2023). The impact of a multidisciplinary team approach on the management of focal pancreatic lesions: a single tertiary center experience. Annals of Gastroenterology, 36(5), 580-587. doi:10.20524/aog.2023.0827
  4. 4. Moeremans, M., Avni, F. E., D'Haene, N., Lam, N. M., Metens, T., & D'Hondt, A. (2023). Combined prenatal US and post-mortem fetal MRI: can they replace conventional autopsy for fetal body abnormalities? European radiology. doi:10.1007/s00330-023-09847-y
  5. 5. Racu, M.-L., Bernardi, D., Chaouche, A., Zindy, E., Navez, J., Loi, P., Maris, C., Closset, J., Van Laethem, J.-L., Decaestecker, C., Salmon, I., & D'Haene, N. (2023). SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy. Cancers (Basel), 15(15). doi:10.3390/cancers15153765
  6. 6. Demols, A., Rocq, L., Perez-Casanova Garcia, L., Charry, M., De Nève, N., Ramadhan, A. M., Van Campenhout, C., De Clercq, S., Maris, C., Closset, J., Lucidi, V., Salmon, I., & D'Haene, N. (2023). A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas. The oncologist, 28(7), e520-e525. doi:10.1093/oncolo/oyad075
  7. 7. Lebrun, L., Absil, L., Remmelink, M., De Mendonça, R., D'Haene, N., Gaspard, N., Rusu, S., Racu, M.-L., Collin, A., Allard, J., Zindy, E., Schiavo, A. A., De Clercq, S., De Witte, O., Decaestecker, C., Lopes, M. B., & Salmon, I. (2023). SARS-Cov-2 infection and neuropathological findings: a report of 18 cases and review of the literature. Acta neuropathologica communications, 11(78). doi:10.1186/s40478-023-01566-1
  8. 8. Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., Koopmansch, B., D'Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J.-L., & Bellahcène, A. (2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12(10), 1414. doi:10.3390/cells12101414
  9. 9. Dufraing, K., Van Casteren, K., Breyne, J., D'Haene, N., Van Campenhout, C., Vander Borght, S., Zwaenepoel, K., Rouleau, E., Schuuring, E., von der Thüsen, J., & Dequeker, E. (2022). Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders. BMC cancer, 22(1), 736. doi:10.1186/s12885-022-09798-5
  10. 10. Derasse, M., D'Haene, N., Berghmans, T., & Grigoriu, B. D. (2022). Liquid Biopsy for Detection of T790M Mutation in Patient with EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Case Report. Annals of clinical research, 7, 2361.
  11. 11. Pasau, T., Wauters, E., Wauters, I., Duplaquet, F., Pirard, L., Stanciu-Pop, C., D'Haene, N., Dupont, M., Vander Borght, T., Rondelet, B., & Ocak, S. (2022). Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. Frontiers in oncology, 12, 985446. doi:10.3389/fonc.2022.985446
  12. 12. Racu, M.-L., Lebrun, L., Schiavo, A. A., Van Campenhout, C., De Clercq, S., Absil, L., Minguijon Perez, E., Maris, C., Decaestecker, C., Salmon, I., & D'Haene, N. (2022). The Role of SMAD4 Inactivation in Epithelial-Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link? Cancers (Basel), 14(4). doi:10.3390/cancers14040973
    13. << Précédent 1 2 3 4 5 6 7 8 9 Suivant >>